Alerts will be sent to your verified email
Verify EmailINDSWFTLAB
|
Ind-Swift Lab.
|
Venus Remedies
|
Sakar Healthcare
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Total reactor capacity
|
700.0 kL | n/a | n/a |
|
DMF Filingsby API
|
474.0 . | n/a | n/a |
|
R&D as a % of Total Sales
|
2.9 % | n/a | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
14.7 % | 8.87 % | 8.14 % |
|
5yr average Equity Multiplier
|
2.17 | 1.32 | 1.76 |
|
5yr Average Asset Turnover Ratio
|
0.66 | 0.96 | 0.45 |
|
5yr Avg Net Profit Margin
|
16.17 % | 6.91 % | 10.03 % |
|
Price to Book
|
0.92 | 2.09 | 3.91 |
|
P/E
|
4.82 | 16.28 | 41.58 |
|
5yr Avg Cash Conversion Cycle
|
15.71 Days | 46.96 Days | 18.72 Days |
|
Inventory Days
|
103.91 Days | 75.64 Days | 51.79 Days |
|
Days Receivable
|
105.66 Days | 54.28 Days | 53.06 Days |
|
Days Payable
|
107.02 Days | 58.86 Days | 115.64 Days |
|
5yr Average Interest Coverage Ratio
|
21.19 | 396.11 | 4.85 |
|
5yr Avg ROCE
|
12.09 % | 8.42 % | 8.92 % |
|
5yr Avg Operating Profit Margin
|
14.94 % | 10.14 % | 24.94 % |
|
5 yr average Debt to Equity
|
0.91 | 0.08 | 0.49 |
|
5yr CAGR Net Profit
|
n/a | -6.01 % | 10.38 % |
|
5yr Average Return on Assets
|
11.49 % | 6.69 % | 4.54 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
42.99 % | 41.76 % | 52.86 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.99 % | 0.0 | -7.86 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Ind-Swift Lab.
|
Venus Remedies
|
Sakar Healthcare
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
-
|
-
|
|
Asset Break-Up
|
Asset Break-Up
|
-
|
-
|